Targeted Therapies in the Treatment of Mantle Cell Lymphoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 May 25

PMID 38792015

Authors

Colin J Thomas

Veronica Carvajal

Stefan K Barta

Affiliations

Soon will be listed here.

Abstract

Mantle cell lymphoma (MCL) is a rare, heterogeneous B-cell non-Hodgkin's lymphoma. The standard front-line treatment utilizes chemotherapy, often followed by consolidation with an autologous hematopoietic cell transplant; however, in most patients, the lymphoma will recur and require subsequent treatments. Additionally, mantle cell lymphoma primarily affects older patients and is frequently chemotherapy-resistant, which has further fostered the necessity for new, chemotherapy-free treatment options. In the past decade, targeted therapies in mantle cell lymphoma have been practice-changing as the treatment paradigm shifts further away from relying primarily on cytotoxic agents. Here, we will review the pathophysiology of mantle cell lymphoma and discuss the emergence of targeted, chemotherapy-free treatments aimed at disrupting the abnormal biology driving its lymphomagenesis. Treatments targeting the constitutive activation of NF-kB, Bruton's Tyrosine Kinase signaling, and anti-apoptosis will be the primary focus as we discuss their clinical data and toxicities. Our review will also focus primarily on the emergence and use of targeted therapies in the relapsed/refractory setting but will also discuss the emergence of their use in front-line therapy and in combination with other agents.

References

Eskelund C, Dahl C, Hansen J, Westman M, Kolstad A, Pedersen L . mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017; 130(17):1903-1910. DOI: 10.1182/blood-2017-04-779736. View

Dengler M, Teh C, Thijssen R, Gangoda L, Lan P, Herold M . Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. Oncogene. 2019; 39(9):2009-2023. DOI: 10.1038/s41388-019-1122-x. View

Zinzani P, Vose J, Czuczman M, Reeder C, Haioun C, Polikoff J . Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol. 2013; 24(11):2892-7. PMC: 3811905. DOI: 10.1093/annonc/mdt366. View

Phillips T, Bond D, Takiar R, Kump K, Kandarpa M, Boonstra P . Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma. Blood Adv. 2023; 7(16):4518-4527. PMC: 10425679. DOI: 10.1182/bloodadvances.2023009992. View

Eyre T, Walter H, Iyengar S, Follows G, Cross M, Fox C . Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2018; 104(2):e68-e71. PMC: 6355471. DOI: 10.3324/haematol.2018.198812. View

Khoury J, Medeiros L, Rassidakis G, McDonnell T, Abruzzo L, Lai R . Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol. 2002; 199(1):90-7. DOI: 10.1002/path.1254. View

Desai M, Newberry K, Ou Z, Wang M, Zhang L . Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective. Ther Adv Hematol. 2014; 5(3):91-101. PMC: 4031905. DOI: 10.1177/2040620714532124. View

Sharma S, Galanina N, Guo A, Lee J, Kadri S, Van Slambrouck C . Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. 2016; 7(42):68833-68841. PMC: 5356593. DOI: 10.18632/oncotarget.11932. View

Thorpe L, Yuzugullu H, Zhao J . PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2014; 15(1):7-24. PMC: 4384662. DOI: 10.1038/nrc3860. View

10.

Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O . Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015; 372(10):944-53. DOI: 10.1056/NEJMoa1412096. View

11.

Pham L, Tamayo A, Yoshimura L, Lo P, Ford R . Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003; 171(1):88-95. DOI: 10.4049/jimmunol.171.1.88. View

12.

Dreyling M, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Trneny M . Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2015; 387(10020):770-8. DOI: 10.1016/S0140-6736(15)00667-4. View

13.

Jain P, Zhao S, Lee H, Hill H, Ok C, Kanagal-Shamanna R . Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol. 2021; 40(2):202-212. PMC: 8718245. DOI: 10.1200/JCO.21.01797. View

14.

Yuda J, Will C, Phillips D, Abraham L, Alvey C, Avigdor A . Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Commun Med (Lond). 2023; 3(1):154. PMC: 10600239. DOI: 10.1038/s43856-023-00380-z. View

15.

Wang M, Robak T, Maddocks K, Phillips T, Smith S, Gallinson D . Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis. Blood Adv. 2024; 8(17):4539-4548. PMC: 11399641. DOI: 10.1182/bloodadvances.2023012424. View

16.

Pratt G, Yap C, Oldreive C, Slade D, Bishop R, Griffiths M . A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. Br J Haematol. 2017; 182(3):429-433. DOI: 10.1111/bjh.14793. View

17.

Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E . A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003; 101(12):4975-81. DOI: 10.1182/blood-2002-06-1864. View

18.

Novak U, Fehr M, Schar S, Dreyling M, Schmidt C, Derenzini E . Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13). EClinicalMedicine. 2023; 64:102221. PMC: 10541470. DOI: 10.1016/j.eclinm.2023.102221. View

19.

Damle R, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6):1840-7. View

20.

Gill S, Vides V, Frey N, Hexner E, Metzger S, OBrien M . Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022; 6(21):5774-5785. PMC: 9647791. DOI: 10.1182/bloodadvances.2022007317. View